Riluzole for treatment-resistant obsessive-compulsive disorder

Primary Psychiatry

Volumn 12, Issue 10, 2005, Pages 33-34

  Ginsberg, David L ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BUSPIRONE; CLOMIPRAMINE; CLONAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; OLANZAPINE; QUETIAPINE; RILUZOLE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; HAMILTON SCALE; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION TEST; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; REVIEW; SCORING SYSTEM; SIDE EFFECT; TREATMENT FAILURE;

EID: 27444445653     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. RILUTEK (riluzole) tablets [package insert]. Bridgewater, NJ: Aventis Pharmaceuticals; 2003.
2. Zarate CA, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004;161(1):171-174.
3. Mathew SJ, Amiel JM, Coplan JD, et al. Riluzole in generalized anxiety disorder: an open-label trial. Neuropsychopharmacol. 2004;29(suppl 1):S154.
4. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry. 2005;58(5):424-428.
5. Rilutek. In: Physician's Desk Reference. Montvale, NJ: Thompson Healthcare; 2004.
6. Jehle T, Bauer J, Blauth E, et al. Effects of riluzole on electrically evoked neurotransmitter release. Br J Pharmacol 2000;130(6):1227-1234.
7. Urbani A, Belluzzi O. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci. 2000;12(10):3567-3574.
8. Mathew SJ, Shungu DC, Mao X, et al. A magnetic resonance spectroscopic imaging study of adult nonhuman primates exposed to early-life stressors. Biol Psychiatry. 2003;54(7):727-735.
9. Coplan JD, Mathew SJ, Smith ELP, et al. Effects of LY354740, a novel glutamatergic metabotropic agonist, on nonhuman primate hypothalamic-pituitary- adrenal axis and noradrenergic function. CNS Spectr. 2001;6:607-617.
10. Davis M, Myers KM. The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy. Biol Psychiatry. 2002;52(10):998-1007.